BsAbs have a myriad of different formats that can vary with respect to molecular weight, antigen‐binding site valency, receptor affinity, spatial relationship between moieties, Fc‐mediated effector functions95, 96, 97 etc. Early‐phase clinical trials for solid tumour indications have shown promise with BsAbs simultaneously targeting different immune receptors including tumour intrinsic IC‐protein such as PD‐1/L1, CTLA‐4 and LAG3.98, 99. The gene discussed is CTLA4; the disease is neoplasm.